Literature DB >> 18811122

Short chain aliphatic beta-nitro alcohols for corneoscleral cross-linking: corneal endothelial toxicity studies.

David C Paik1, Quan Wen, Richard E Braunstein, Stephen L Trokel.   

Abstract

PURPOSE: Recent studies suggest that short chain aliphatic beta-nitro alcohols can cross-link corneoscleral tissue under physiologic conditions. The present study was conducted to determine the cytotoxic threshold for these agents in vitro and to draw comparisons to commonly used topical ophthalmic agents.
METHODS: Primary cultures of bovine corneal endothelial cells were grown to confluence in 24- and 96-well plates using standard protocol. The cells were exposed to three beta-nitro alcohols, 2-nitroethanol, 2-nitro-1-propanol, and 3-nitro-2-pentanol in a range of concentrations from 0.1 to 10 mM. After a 48-hour exposure, cell necrosis and apoptosis were evaluated using trypan blue, propidium iodide, and annexin V staining. In addition, a review of the ophthalmic literature was conducted to derive comparisons with agents commonly used in clinical practice.
RESULTS: An all-or-none response was observed for each compound. Positive staining with trypan blue, propidium iodide, and annexin V occurred at identical concentrations. The most toxic of the group was 2-nitro-1-propanol. The cytotoxic level for 2-nitroethanol, 2-nitro-1-propanol, and 3-nitro-2-pentanol was 3 mM (0.0273%), 1 mM (0.0105%), and 3 mM (0.0399%), respectively. Furthermore, by comparison with several agents used in ophthalmic practice such as fluoroquinolone antibiotics, anti-proliferative agents, and benzalkonium chloride, the beta-nitro alcohols exhibit less toxicity in vitro.
CONCLUSIONS: Short chain aliphatic beta-nitro alcohols exhibit favorable in vitro toxicity thresholds. The result of this study encourages further evaluation of these compounds as potential pharmacologic topical stiffening agents for corneoscleral disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18811122     DOI: 10.3928/1081597X-20080901-19

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  8 in total

1.  Using the Griess colorimetric nitrite assay for measuring aliphatic β-nitroalcohols.

Authors:  Quan Wen; David C Paik
Journal:  Exp Eye Res       Date:  2012-03-03       Impact factor: 3.467

2.  Pharmacologic alternatives to riboflavin photochemical corneal cross-linking: a comparison study of cell toxicity thresholds.

Authors:  MiJung Kim; Anna Takaoka; Quan V Hoang; Stephen L Trokel; David C Paik
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-10       Impact factor: 4.799

3.  Initial studies using aliphatic beta-nitro alcohols for therapeutic corneal cross-linking.

Authors:  David C Paik; Quan Wen; Richard E Braunstein; Suzanna Airiani; Stephen L Trokel
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-03       Impact factor: 4.799

4.  Mechanistic and Catalytic Studies of β-Nitroalcohol Crosslinking with Polyamine.

Authors:  Xia Li; Yongjun Li; Yi Rao; Marissa R Solomon; David C Paik; Nicholas J Turro
Journal:  J Appl Polym Sci       Date:  2013-06-15       Impact factor: 3.125

5.  Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: corneal permeability considerations.

Authors:  Quan Wen; Stephen L Trokel; MiJung Kim; David C Paik
Journal:  Cornea       Date:  2013-02       Impact factor: 2.651

6.  Nitroalcohol Induced Hydrogel Formation in Amine-Functionalized Polymers.

Authors:  Marissa R Solomon; Naphtali A O'Connor; David C Paik; Nicholas J Turro
Journal:  J Appl Polym Sci       Date:  2010-07-15       Impact factor: 3.125

Review 7.  Roles of Nitrocompounds in Inhibition of Foodborne Bacteria, Parasites, and Methane Production in Economic Animals.

Authors:  Po-Yun Teng; Woo Kyun Kim
Journal:  Animals (Basel)       Date:  2021-03-24       Impact factor: 2.752

Review 8.  Biomechanics of Ophthalmic Crosslinking.

Authors:  Brecken J Blackburn; Andrew M Rollins; William J Dupps
Journal:  Transl Vis Sci Technol       Date:  2021-04-29       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.